» Articles » PMID: 16618417

Mice Deleted for Fatty Acid Transport Protein 5 Have Defective Bile Acid Conjugation and Are Protected from Obesity

Overview
Specialty Gastroenterology
Date 2006 Apr 19
PMID 16618417
Citations 55
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aims: Fatty Acid Transport Protein 5 (FATP5) is a liver-specific member of the FATP/Slc27 family, which has been shown to exhibit both fatty acid transport and bile acid-CoA ligase activity in vitro. Here, we investigate its role in bile acid metabolism and body weight homeostasis in vivo by using a novel FATP5 knockout mouse model.

Methods: Bile acid composition was analyzed by mass spectroscopy. Body weight, food intake, energy expenditure, and fat absorption were determined in animals fed either a low- or a high-fat diet.

Results: Although total bile acid concentrations were unchanged in bile, liver, urine, and feces of FATP5 knockout mice, the majority of gallbladder bile acids was unconjugated, and only a small percentage was conjugated. Primary, but not secondary, bile acids were detected among the remaining conjugated forms in FATP5 deletion mice, suggesting a specific requirement for FATP5 in reconjugation of bile acids during the enterohepatic recirculation. Fat absorption in FATP5 deletion mice was largely normal, and only a small increase in fecal fat was observed on a high-fat diet. Despite normal fat absorption, FATP5 deletion mice failed to gain weight on a high-fat diet because of both decreased food intake and increased energy expenditure.

Conclusions: Our findings reveal an important role for FATP5 in bile acid conjugation in vivo and an unexpected function in body weight homeostasis, which will require further analysis. FATP5 deletion mice provide a new model to study the intersection of bile acid metabolism, lipid metabolism, and body weight regulation.

Citing Articles

Unravelling the therapeutic landscape of bile acid-based therapies in gastrointestinal disorders.

Alrehaili B Saudi J Gastroenterol. 2024; 30(5):283-293.

PMID: 38708898 PMC: 11534188. DOI: 10.4103/sjg.sjg_53_24.


Examining the Pathogenesis of MAFLD and the Medicinal Properties of Natural Products from a Metabolic Perspective.

Fu Y, Wang Z, Qin H Metabolites. 2024; 14(4).

PMID: 38668346 PMC: 11052500. DOI: 10.3390/metabo14040218.


The Interconnection between Hepatic Insulin Resistance and Metabolic Dysfunction-Associated Steatotic Liver Disease-The Transition from an Adipocentric to Liver-Centric Approach.

Veskovic M, Sutulovic N, Hrncic D, Stanojlovic O, Macut D, Mladenovic D Curr Issues Mol Biol. 2023; 45(11):9084-9102.

PMID: 37998747 PMC: 10670061. DOI: 10.3390/cimb45110570.


Loss of SLC27A5 Activates Hepatic Stellate Cells and Promotes Liver Fibrosis via Unconjugated Cholic Acid.

Wu K, Liu Y, Xia J, Liu J, Wang K, Liang H Adv Sci (Weinh). 2023; 11(2):e2304408.

PMID: 37957540 PMC: 10787101. DOI: 10.1002/advs.202304408.


Reduced Expression of Very-Long-Chain Acyl-CoA Synthetases and in the Glioblastoma Tumor Compared to the Peritumoral Area.

Korbecki J, Kojder K, Jezewski D, Siminska D, Tomasiak P, Tarnowski M Brain Sci. 2023; 13(5).

PMID: 37239243 PMC: 10216168. DOI: 10.3390/brainsci13050771.